Global Valsartan Hydrochlorothiazide Drug Market Size, Share and Trends Analysis Report, By Type (80 mg/12.5 mg, 160 mg/12.5 mg, 320 mg/12.5 mg, 160 mg/25 mg, and 320 mg/25 mg), Forecast (2022-2028)

The global valsartan hydrochlorothiazide drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Valsartan and hydrochlorothiazide are used in combination and are given together for the treatment of high blood pressure. Due to high blood pressure, the heart and its arteries are pressurized and the veins connected to their contract and relax. This poses a threat to the overall blood circulation system and can lead to dysfunction in the heart. It can also lead to damage of blood vessels of the brain, kidneys, and other body organs. High blood pressure leads to an increased risk of stroke and paralysis. Valsartan is considered an angiotensin 2 receptor blocker. It works in reducing those factors in the body which leads to tightening of blood vessels. This drug relaxes the blood vessels and supports in lowering blood pressure. On the other hand, hydrochlorothiazide is considered a thiazide diuretic that works as a water pill. It increases the flow of urine, which in turn, supports in reducing salt content in the body. This drug is available in tablet form.

An increase in hypertension problems in the younger generation is expected to drive the market during the forecast period. For instance, in Jan 2022, the Food and Drug Administration of the US has approved bisoprolol fumarate and hydrochlorothiazide tablet. This tablet is produced by Glenmark Pharmaceuticals Ltd. and is used in the treatment of hypertension or high blood pressure. This drug is a generic version of Ziac tablets which are manufactured by Teva Pharmaceutical Ltd. As per the data obtained by IQVIA for the 12 month period till November 2021, annual sales of $30.3 million were done by the Ziac tablet market. Glenmark Pharmaceuticals Ltd. currently has 172 products that are authorized for distribution in the US and around 46 drug approvals pending with Food and Drug Administration US. The company has its operations in over 50 countries and has a stronghold on generics, specialty, and over-the-counter business.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Novartis International AG, Glenmark Pharmaceutical Ltd., and Teva Pharmaceutical Industries Ltd., among others.
• Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Valsartan Hydrochlorothiazide Drug Market Report by Segment

By Type

• 80 mg/12.4 mg
• 160 mg/12.5 mg
• 320 mg/12.5 mg
• 160 mg/25 mg
• 320 mg/25 mg

Valsartan Hydrochlorothiazide Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa